An observational study in Obstructive Apnea, Diagnostic and Sleep Apnea Syndrome (OSAS), sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by Insel Gruppe AG, University Hospital Bern · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Sleep Apnea, Obstructive with a site in Switzerland — 6 open to participants now, 8 under way, none of them phase 3. Sleep Apnea, Obstructive · Switzerland.
Among the 53 studies in Sleep Apnea, Obstructive with a site in Switzerland, this one is the 10th largest by planned enrollment of the 22 observational ones that give a count, is the only one that started in 2026, is one of 22 observational ones, and was the 53rd registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →6 of the 53 studies in Sleep Apnea, Obstructive with a site in Switzerland are open now. Recruiting first, the newest first:
Stefan Lakämper · Sites in Switzerland
Ages 18+ · Healthy volunteers
Inspire Medical Systems, Inc. · Sites in Switzerland, Austria, Belgium and 4 more countries
Ages 18+
Solelhac Geoffroy · Sites in Switzerland
Ages 18+
Wissenschaftliches Institut Bethanien e.V · Sites in Switzerland, Belgium, France and 8 more countries
Ages 40+
Dr. Med Anas Taha · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 1 · Phase 4 4
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 192 is above the median of 105 across 668 observational studies indexed under Sleep Apnea, Obstructive.
Median enrollment 47 across the 30 interventional studies, 162 across the 22 observational. Of the 39 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 53 have an industry lead sponsor. The 10 most frequent:
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
Insel Gruppe AG, University Hospital Bern has 3 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
3 of the studies in Sleep Apnea, Obstructive with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06397365Solelhac GeoffroyEffect of Hypnosis on Adherence to Continuous Positive Airway Pressure. | 2027-02 |
| NCT06872593Stefan LakämperValidating a Novel Driving Simulation-based MWT Against the Standard MWT in an OSA-cohort Challenged by CPAP-withdrawal | 2027-04-30 |
| NCT07555119Insel Gruppe AG, University Hospital BernNight-to-Night Variability of Novel Physiological Parameters in Home Sleep Apnea Testing | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 53 studies in Sleep Apnea, Obstructive with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Obstructive sleep apnea (OSA) is usually diagnosed from a single night of home sleep apnea testing using the apnea-hypopnea index (AHI). However, the AHI varies substantially from night to night, undermining diagnostic accuracy, and shows only modest correlation with symptoms. This variability further limits its usefulness for predicting cardiovascular and other complications. Besides the traditional AHI, more robust physiological markers are needed.
Several emerging physiological metrics - hypoxic burden, ventilatory burden, heart rate variability, autonomic arousals, and the pulse wave amplitude drop index - capture the physiological impact of OSA more comprehensively and demonstrate stronger associations with cardiovascular risk. Despite this promise, their night-to-night variability has not been studied.
A systematic evaluation of both established and novel OSA metrics across nights is essential to identify reliable, stable parameters suitable for clinical routine. This improves diagnostic precision beyond what traditional metrics can provide, enhances patient selection, reduces costs and patient harm, and may improve treatment outcomes.
Participants with suspected or diagnosed sleep-disordered breathing of any severity will be recruited at Inselspital University Hospital und University Bern.
No selection or stratification based on sex, gender, or any other patient characteristics is applied during recruitment. Participants are included consecutively based on the clinical indication for home sleep apnea testing, irrespective of sex or gender. Any resulting imbalance reflects the underlying clinical population and does not compromise the scientific validity of the study, as analyses will account for sex and gender as covariates and report their effects transparently.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo repeated sleep testing using respiratory polygraphy over 4 nights and oximetry over 10 nights, starting in parallel. Before and after the recordings they will fill out symptom questionnaires and patient-reported outcome measures.
Night-to-night variability of apnea-hypopnea index (events per hour of sleep) over 4 nights
The variability of the apnea-hypopnea index (events per hour of sleep) over 4 nights will be quantified using linear mixed-effects models, accounting for confounding variables.
Time frame: 4 nights of respiratory polygraphy
Night-to-night variability of oxygen desaturation index (events per hour of sleep) over 10 nights
The variability will be quantified using linear mixed-effects models, accounting for confounding variables.
Time frame: 4 nights of respiratory polygraphy and 10 nights of oxymetry
Night-to-night variability of hypoxic burden (minute x percent per hour of sleep) over 10 nights
The variability will be quantified using linear mixed-effects models, accounting for confounding variables.
Time frame: 4 nights of respiratory polygraphy and 10 nights of oxymetry
Night-to-night variability of ventilatory burden over 4 nights
The variability will be quantified using linear mixed-effects models, accounting for confounding variables. Ventilatory burden will be calculated according to Parekh et al.
Time frame: 4 nights of respiratory polygraphy
Night-to-night variability of heart rate variability over 10 nights
The variability will be quantified using linear mixed-effects models, accounting for confounding variables.
Time frame: 4 nights of respiratory polygraphy and 10 nights of oxymetry
Night-to-night variability of pulse wave amplitude drops (events per hour) over 10 nights
The variability will be quantified using linear mixed-effects models, accounting for confounding variables.
Time frame: 4 nights of respiratory polygraphy and 10 nights of oxymetry
Identification of factors contributing to and explaining variability
Each influencing factor will be evaluated on its potential to explain the observed variability in the objective physiological parameters listed above. Each factor will be included individually as a fixed effect in the mixed-effects model and tested for significance. The following factors will be analyzed: * Age (years) * Body mass index (kg(m2) * Gender * Upper airway anatomy (tonsil size) * Mean OSA severity over all nights (of the respective parameter) * Sleep position (supine time as a percent of sleep time) * Alcohol consumption (number of drinks) * Caffeine intake (number of cups) * Nicotine use (number of packages) * Sleep Medication (free text) * Subjective sleep quality (visual analog scale, VAS, 0 to 10 points) * Snoring intensity (VAS, 0 to 10 points) * Daytime sleepiness on a VAS of the subsequent day (0 to 10 points) * Daytime sleepiness on the Epworth Sleepiness Scale of the subsequent day (0 to 24 points) * Respiratory symptoms such as infection (VAS) * Allergy symptoms
Time frame: 4 nights of respiratory polygraphy and 10 nights of oxymetry
Correlation between physiological parameters from sleep testing and patient-reported outcome measures (PROMs)
Associations between physiological metrics and PROMs will be assessed using mixed-effects models, analogously to the analysis of influencing factors above and correlation analysis (Spearman's rank coefficient). Patient-reported symptoms for correlation analyses: * Sleep quality on a VAS (0 to 10 points) * Snoring intensity on a VAS (0 to 10 points) * Daytime sleepiness on a VAS (0 to 10 points) * Epworth Sleepiness Scale (0 to 24 points)
Time frame: 4 nights of respiratory polygraphy and 10 nights of oxymetry
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.
Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 11 months is below that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →